CN107823337A - A kind of allergic rhinitis oil formula and its preparation technology - Google Patents
A kind of allergic rhinitis oil formula and its preparation technology Download PDFInfo
- Publication number
- CN107823337A CN107823337A CN201711124228.1A CN201711124228A CN107823337A CN 107823337 A CN107823337 A CN 107823337A CN 201711124228 A CN201711124228 A CN 201711124228A CN 107823337 A CN107823337 A CN 107823337A
- Authority
- CN
- China
- Prior art keywords
- oil
- allergic rhinitis
- ozone
- parts
- mixed liquor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 38
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 38
- 238000005516 engineering process Methods 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000003921 oil Substances 0.000 claims abstract description 41
- 235000019198 oils Nutrition 0.000 claims abstract description 41
- 239000004006 olive oil Substances 0.000 claims abstract description 21
- 235000008390 olive oil Nutrition 0.000 claims abstract description 21
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims abstract description 19
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 19
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 19
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 19
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 19
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 18
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940041616 menthol Drugs 0.000 claims abstract description 18
- 238000005057 refrigeration Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 238000005138 cryopreservation Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000012360 testing method Methods 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 17
- 210000001331 nose Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 208000030961 allergic reaction Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000011086 glassine Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- -1 invalid afterwards Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to rhinitis oil tech field, a kind of allergic rhinitis oil formula of proposition, it is made up of the raw material of following parts by weight：0.5 part of 80~90 parts of olive oil, 9.5~19.5 parts of tea tree ethereal oil and Tea Polyphenols；Also include 1 part of menthol.A kind of allergic rhinitis oil making technology is also proposed, is comprised the following steps：Raw material mixes：Olive oil, tea tree ethereal oil, Tea Polyphenols and menthol are mixed according to parts by weight described in above-mentioned allergic rhinitis oil formula；Ozone oxidation：Ozone is added into mixed liquor, forms stable ozone mixed liquor；Refrigeration：After ozone mixed liquor is placed into refrigerator refrigeration a period of time, finished product is made.Present inventive concept is ingenious, easy to operate, solves in the prior art that drug for treating rhinitis is numerous, but the technical problem that using effect is less desirable.
Description
Technical field
The invention belongs to rhinitis oil tech field, is related to a kind of allergic rhinitis oil formula and its preparation technology.
Background technology
Allergic rhinitis is allergic rhinitis, after referring to atopic individuals contact allergen, mainly by the medium of IgE mediations
(mainly histamine) release, and have the schneiderian membrance non-infectious inflammatory disease of the participations such as panimmunity competent cell and cell factor
Disease.Its necessary condition occurred has 3：Specific antigen is the material for causing organism immune response；Atopic individuals are so-called
Individual difference, allergic constitution；Specific antigen answers both type individuals to meet with spy.Allergic rhinitis are that a global health is asked
Topic, can cause many diseases and disability.Existing drug for treating rhinitis on the market is numerous, but using effect is less desirable.
The content of the invention
The present invention proposes a kind of allergic rhinitis oil formula and its preparation technology, and it is many to solve drug for treating rhinitis in the prior art
It is more, but the technical problem that using effect is less desirable.
The technical proposal of the invention is realized in this way：
A kind of allergic rhinitis oil formula, is made up of the raw material of following parts by weight：
0.5 part of 80~90 parts of olive oil, 9.5~19.5 parts of tea tree ethereal oil and Tea Polyphenols.
As further technical scheme, in addition to 1 part of menthol.
As further technical scheme, it is made up of the raw material of following parts by weight：
1 part of olive oil 86,15.5 parts of tea tree ethereal oil, 0.5 part of Tea Polyphenols and menthol.
A kind of allergic rhinitis oil making technology, comprises the following steps：
Raw material mixes：By olive oil, tea tree ethereal oil, Tea Polyphenols and menthol according to a kind of allergic rhinitis oil formula
The parts by weight are mixed；
Ozone oxidation：Ozone is added into mixed liquor, forms stable ozone mixed liquor；
Refrigeration：After ozone mixed liquor is placed into refrigerator refrigeration a period of time, finished product is made.
As further technical scheme, it is 40mg/L that ozone concentration is added in ozone oxidation step, the addition of ozone
Amount and the volumetric ratio of the addition of olive oil are 1：1.
As further technical scheme, refrigerated storage temperature is 4~8 DEG C in cryopreservation step, and cold preservation time is 12 hours.
Use principle of the present invention and have the beneficial effect that：
In the prescription that the present invention uses：
Olive oil：Rich in monounsaturated fatty acids, can increasing HDL-C, (one kind is in our blood
The good cholesterol of flowing), and reduce bad cholesterol.It also has the effect of anti-inflammatory, all beneficial to blood vessel and joint, Er Qiefu
Black alcohols of the plant and polyphenols containing protective effect on cancer risk.
Tea tree ethereal oil：With bactericidal antiphlogistic, restrain pore, treatment cold, cough, rhinitis, asthma, improve dysmenorrhoea,
Irregular menstruation and genital infection and other effects.
Tea Polyphenols：The release action of suppression histamine that can be strong, experiment prove Tea Polyphenols antiallergic action and anti-skin mistake
The inhibition of the quick reaction antiallergic more conventional than currently is strong 2~10 times.In the Tea Polyphenols energy inhibitory activity factor such as antibody, kidney
Allergy caused by parathyrine, enzyme etc. reflects, has significant curative effect to allergic conditions such as asthma.
Menthol：White crystal, molecular formula C10H20O, it is peppermint and lavender essence by being extracted in the leaf and stem of peppermint
Main component in oil, in medicine as excitants, skin or mucous membrane are acted on, there is refrigerant itching-relieving action；Taking orally can conduct
Carminative, for headache and nose；Pharynx；Laryngitis etc..
Ozone：Ozone Water sterilization is that rapidly, disinfective action occurs in moment.Clear Measuring Ozone Concentration in Water once reaches
Arrive, bacterium was just killed in 0.5~1 minute, reaches 4mg/L in concentration, hepatitis B inactivation ratio is 100% in 1 minute.
Schneiderian membrance surface is sterilized first using tea tree ethereal oil after the present invention, menthol and olive oil promote in nasal cavity
Blood flow in capillary, allows medicine quickly to take in, and menthol and olive oil can also play anti-inflammatory, antipruritic in the process
Effect, penetrates into the tea tree ethereal oil of mucous membrane tissue and ozone and menthol and olive oil cooperate and sterilized and repair,
And this product is oiliness medicament, there is very strong moisture-keeping function, layer protecting film is formd in nasal cavity, has isolated anaphylactogen
Intrusion, in addition tea tree ethereal oil also have convergence pore the effect of, rhinitis oil complete sterilization after, can to mucous membrane tissue carry out very
Good astriction, reduce further the risk of outside bacterium or anaphylactogen intrusion bronchia mucosal, it is ensured that sufferer it is thorough
Cure.In addition, allergic rhinitis oil proposed by the invention is pure natural substance formula using component, Western medicine is avoided to people
The injury of body, safe without toxic side effect, pregnant woman, child can use, and antibacterial, repair are good.
To confirm the safety in utilization and bactericidal effect of medicine of the present invention, the present invention is delivered to Guangdong Province microorganism point by us
Analysis inspection center, which has carried out vaginal mucosa, stimulates detection, skin allergic reaction detection and Suspension quantitative bactericidal test, submitted sample
Quantity is 30 bottles, and 20ml/ bottles, the date of manufacture is on December 12nd, 2016, and sample state is faint yellow finish, and the sample presentation time is
On December 19th, 2016, detection deadline are on April 1,15 days~2017 January in 2017, and wherein vaginal mucosa stimulates inspection
Survey, skin allergic reaction detection and Suspension quantitative bactericidal test detection foundation are《Disinfection technology standard》Version in 2002, liquid
According to being GB15979-2002, active ingredient (with ozonometer) content detection foundation is Q/CYK-2016 for interior clump count detection.
Vaginal mucosa stimulates detection case as follows：
First, tested substance：
Allergic rhinitis oil stoste
2nd, experimental animal
1st, regular grade Animal House, experimental animal use credit number：SYXK (Guangdong) 2016-0156
2nd, animal species strain：Regular grade new zealand rabbit, animal quality certification number：44411600003177
3rd, animal origin：Experimental animal is provided by Guangdong Medical Lab Animal Center.
3rd, method：
The method of inspection：《Disinfection technology standard》Version in 2002, Part II 2.3.5
Testing conditions：22~25 DEG C of environment temperature, relative humidity 40~70%
4th, test procedure：
Face upward fixed animal during experiment, exposure introitus, blunt nosed flexible pipe is connected with syringe, extracts 2ml tested materials, moistening
Flexible pipe, introitus about 4~5cm is inserted, is slowly injected into physiological saline.The liquid spilt is wiped with gauze.After 24h, air tap is used
Plug method puts to death animal, dissection, completely takes out vagina, longitudinally splits, and observes epithelial tissue.Fixed at least with 10% formalin
24h, vagina both ends and central part is taken to make paraffin section, HE dyeing, Microscopic observation.
5th, evaluation of result：
Histopathological examination result, scored according to vaginal mucosa stimulate the reaction standards of grading.By test group and right
After being added respectively to 3 animals, 3 position stimulate the reaction integrations according to group divided by observation is total, obtains average response integration, maximum
Score as 16 points.The average integral that the average integral of test group is subtracted to control group obtains stimulus index, is pierced according to vaginal mucosa
Swash strength grading table to be classified.
6th, result of the test：
After the stimulate the reaction integration at 3 positions of every group of 3 animals is added divided by observation total (number of animals * 3) produces
Stimulate the reaction average integral；Stimulus index=test group average integral-control group average integral, and then stimulus intensity can be carried out
Classification.
7th, conclusion：
Under this experiment condition, sample " allergic rhinitis oil stoste " is to new zealand rabbit vaginal mucosa stimulate the reaction intensity
It is extremely light.
Skin allergic reaction detection case is as follows：
First, experimental animal：FMMU cavys
2nd, test procedure：
1 Induction exposure：24h is by 4~6cm of experimental animal left dorsal unhairing before experiment2.Respectively will in the 1st, 7 and 14 day
Size about 3*3cm given the test agent is fixed on epilating area on the left of cavy, with two layers of gauze and one layer of glassine paper covering, then with nothing
After stimulating adhesive tape to close fixed 6h, applicator is removed, application region is cleaned with water.
2 excite contact：The 14th day after last induction, size about 3*3cm given the test agent is applied to back on the right side of cavy
Epilating area (24h unhairings before experiment), then covered with two layers of gauze and one layer of glassine paper, then closed and fixed with non-stimulated adhesive tape
After 6h, applicator is removed, application region is cleaned with water.Control group, the same given the test agent of method are set simultaneously, but is only given to excite and connects
Touch, without Induction exposure.
3rd, result of the test：
4th, conclusion：
Under this experiment condition, result that sample " allergic rhinitis oil stoste " is tested FMMU guinea pig skins allergy
To have no skin allergic reaction.
Via vagina mucosa irritation detects and skin allergic reaction testing result understands rhinitis oil proposed by the invention to skin
Skin excitant is small, and without skin allergic reaction, ensure that the security that rhinitis oil of the present invention uses.
Suspension quantitative bactericidal test testing result is as follows：
Allergic rhinitis oil bactericidal effect proposed by the invention can be seen that by Suspension quantitative bactericidal test testing result
Well, to the sterilizing rates of Escherichia coli up to 7.6 or so, the sterilizing rate to staphylococcus aureus is 4.5 or so, to white
The sterilizing rate of candida albicans is 7 or so, and the sterilizing rate to pseudomonas aeruginosa is 17 or so, and the data phase of three groups of test results
When stability is strong.
To confirm the clinical efficacy of medicine of the present invention, We conducted the clinical test of correlation, its clinical test are as follows：
1st, clinical patients data
Randomly selecting the Allergic Rhinitis 100 of 28~70 years old, its average age is 30 years old, wherein male 41,
Women 59.
2nd, test method
The rhinitis oil prepared by patient's embodiment of the present invention 5 is given, rhinitis oil is picked with cotton swab during use, is applied to lower nose
Road, once a day.
3rd, efficacy result
100 patients are divided into two groups of carry out contrast tests, and every group of each 50 people, one group is taken existing treatment of rhinitis on the market
Medicine is treated, and another group is treated using allergic rhinitis oil proposed by the invention, using one group of common drug
28 people of middle healing, up to 56%, patient with slight symptoms is used continuously 3~5 days to take effect cure rate, takes a turn for the better within 10~15 days, controls one or two moon
More, patient with severe symptoms is used continuously three~tetra- months and fully recovered.Ruled by men using in the group of allergic rhinitis oil proposed by the invention 42
More, cure rate is up to 84%, and patient with slight symptoms is taken effect using 1 time, and 5~7 times symptom disappears, and patient with severe symptoms, which is used continuously one month, to fully recover from an illness
More.
4th, clinical safety is evaluated
In treatment clinical course, we are also observed the gas physiological function of patient, it is found that patient does not occur
Other ill symptomses, have no toxic side effect, securely and reliably.
Embodiment
The technical scheme in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example only part of the embodiment of the present invention, rather than whole embodiments.It is common based on the embodiment in the present invention, this area
The every other embodiment that technical staff is obtained under the premise of creative work is not made, belong to the model that the present invention protects
Enclose.
Embodiment 1
80 parts of olive oil, 9.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 1 part of menthol is weighed to be mixed, it is backward mixed
Close in liquid and add ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 4 DEG C
Refrigerator in refrigeration 12 hours, finished product is made afterwards.
Embodiment 2
86 parts of olive oil, 15.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 1 part of menthol is weighed to be mixed, it is backward mixed
Close in liquid and add ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 4 DEG C
Refrigerator in refrigeration 12 hours, finished product is made afterwards.
Embodiment 3
90 parts of olive oil, 19.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 1 part of menthol is weighed to be mixed, it is backward mixed
Close in liquid and add ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 4 DEG C
Refrigerator in refrigeration 12 hours, finished product is made afterwards.
Embodiment 4
86 parts of olive oil, 15.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 1 part of menthol is weighed to be mixed, it is backward mixed
Close in liquid and add ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 8 DEG C
Refrigerator in refrigeration 12 hours, finished product is made afterwards.
Embodiment 5
86 parts of olive oil, 15.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 1 part of menthol is weighed to be mixed, it is backward mixed
Close in liquid and add ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 6 DEG C
Refrigerator in refrigeration 12 hours, finished product is made afterwards.
Embodiment 6
86 parts of olive oil, 15.5 parts of tea tree ethereal oils and 0.5 part of Tea Polyphenols is weighed to be mixed, backward mixed liquor in add
Ozone, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into the refrigerator that refrigerated storage temperature is 6 DEG C
Refrigeration 12 hours, is made finished product afterwards.
Embodiment 7
86 parts of olive oil, 15.5 parts of tea tree ethereal oils, 0.5 part of Tea Polyphenols and 0.5 part of menthol is weighed to be mixed, it is backward
Ozone is added in mixed liquor, until ozone saturation in mixed liquor, then the mixed liquor after addition ozone is placed into refrigerated storage temperature as 6
DEG C refrigerator in refrigeration 12 hours, finished product is made afterwards.
Through long-term test, effect rate of embodiment 6 be less than embodiment 7, and the cure rate of embodiment 6 and 7 is 70% or so, implementation
For the cure rate of example 1~5 more than 78%, the cure rate of wherein embodiment 5 reaches as high as 84%.
Model case 1
Fan so-and-so, female, 11 years old, suffer from allergic rhinitis 2 years, oral medicine is invalid, using this rhinitis oil, once nasal obstruction, rhiocnesmus
Etc. symptom mitigation, 7 times symptom disappears.
Model case 2
Zhao so-and-so, man, 32 years old, suffer from bacillary rhinitis, allergic rhinitis, oral western medicine is alleviated, secondary using this rhinitis oil
The symptom mitigation such as nasal obstruction, yellow tears, rhiocnesmus, 10 times symptom disappears.
Model case 3
Sun, female, 11 years old, suffer from allergic rhinitis, existing nose drops are alleviated on the market for use, are carried using the present invention
Go out rhinitis oil once to have a stuffy nose alleviation, symptom of having a stuffy nose after five times disappears.
Model case 4
Zhao, female, 33 years old, concha was loose, and allergic rhinitis, oral western medicine is invalid, and externally applied spray is alleviated, and uses the present invention
Itd is proposed rhinitis oil puts down nasal meatus, and 7 times symptom disappears.
Model case 5
Zhang, female, 34 years old, suffer from allergic rhinitis, oral anti-allergy medicine is done well, and be discontinued nasal obstruction, rhiocnesmus, uses the present invention
Itd is proposed rhinitis oil puts down nasal meatus, is had a stuffy nose after 7 times, rhiocnesmus symptom disappears.
Model case 6
Mr. Li, male, 37 years old, suffer from allergic rhinitis, oral Biyan Ning is invalid, is put down using rhinitis oil proposed by the invention
Nasal meatus, has a stuffy nose after 1 time and alleviates, and symptom of being had a stuffy nose after 7 times disappears.
Model case 7
Mr. Li, male, 11 years old, suffer from allergic rhinitis, it is invalid using Biyan Ning spray, use rhinitis proposed by the invention oil
Nasal meatus is put down, symptom of being had a stuffy nose after 5 times disappears.
Model case 8
Zhu, man, 28 years old, suffers from allergic rhinitis, oral BIYANKANG is invalid, is put down using rhinitis oil proposed by the invention
Nasal meatus, symptom of having a stuffy nose after 5 times disappear.
Model case 9
Mr. Wang, female, 13 years old, suffer from allergic rhinitis 2 years, once oral Chinese and Western medicine, effective when starting medication, invalid afterwards,
Nasal meatus is put down using rhinitis oil proposed by the invention, and a symptom mitigation, symptom of having a stuffy nose after 7 times disappears.
Model case 10
Model so-and-so, female, 18 years old, suffer from allergic rhinitis 4 years, once oral Chinese and Western medicine, effective when starting medication, invalid afterwards,
And other drug for treating rhinitis DeGrains are used, and nasal meatus is put down using rhinitis oil proposed by the invention, is once taken effect, disease after 7 times
Shape disappears.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
God any modification, equivalent substitution and improvements made etc., should be included in the scope of the protection with principle.
Claims (6)
1. a kind of allergic rhinitis oil formula, it is characterised in that be made up of the raw material of following parts by weight：
0.5 part of 80~90 parts of olive oil, 9.5~19.5 parts of tea tree ethereal oil and Tea Polyphenols.
2. a kind of allergic rhinitis oil formula according to claim 1, it is characterised in that also including 1 part of menthol.
3. a kind of allergic rhinitis oil formula according to claim 2, it is characterised in that by the raw material of following parts by weight
Composition：
1 part of olive oil 86,15.5 parts of tea tree ethereal oil, 0.5 part of Tea Polyphenols and menthol.
4. a kind of allergic rhinitis oil making technology, it is characterised in that comprise the following steps：
Raw material mixes：By olive oil, tea tree ethereal oil, Tea Polyphenols and menthol according to the described one kind of any one of claims 1~3
Parts by weight described in allergic rhinitis oil formula are mixed；
Ozone oxidation：Ozone is added into mixed liquor, forms stable ozone mixed liquor；
Refrigeration：After ozone mixed liquor is placed into refrigerator refrigeration a period of time, finished product is made.
A kind of 5. allergic rhinitis oil making technology according to claim 4, it is characterised in that institute in ozone oxidation step
Addition ozone concentration is 40mg/L, and the volumetric ratio of the addition of ozone and the addition of olive oil is 1：1.
6. a kind of allergic rhinitis oil making technology according to claim 4 or 5, it is characterised in that cold in cryopreservation step
It is 4~8 DEG C to hide temperature, and cold preservation time is 12 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711124228.1A CN107823337A (en) | 2017-11-14 | 2017-11-14 | A kind of allergic rhinitis oil formula and its preparation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711124228.1A CN107823337A (en) | 2017-11-14 | 2017-11-14 | A kind of allergic rhinitis oil formula and its preparation technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107823337A true CN107823337A (en) | 2018-03-23 |
Family
ID=61655461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711124228.1A Pending CN107823337A (en) | 2017-11-14 | 2017-11-14 | A kind of allergic rhinitis oil formula and its preparation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107823337A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791131A (en) * | 2020-12-30 | 2021-05-14 | 茂名市人民医院 | Nasal cavity cold compress gel pastes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352431A (en) * | 2008-09-16 | 2009-01-28 | 吉林大学 | Medicament for resisting allergic diseases |
| KR101779085B1 (en) * | 2016-06-17 | 2017-09-18 | 한국과학기술연구원 | Anti-allergic composition comprising sphallerocarpus plant extracts |
-
2017
- 2017-11-14 CN CN201711124228.1A patent/CN107823337A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101352431A (en) * | 2008-09-16 | 2009-01-28 | 吉林大学 | Medicament for resisting allergic diseases |
| KR101779085B1 (en) * | 2016-06-17 | 2017-09-18 | 한국과학기술연구원 | Anti-allergic composition comprising sphallerocarpus plant extracts |
Non-Patent Citations (4)
| Title |
|---|
| 奶茶姐姐SUNNY: "臭氧历史简介", 《百度文库》 * |
| 王汝龙 等: "《新编临床药物手册》", 30 April 1999, 重庆出版社 * |
| 花蝶: "《爱上精油：给女人的第一本精油全书》", 31 October 2015, 黑龙江科学技术出版社 * |
| 邓佳刚: "《中药新家族——化学中药》", 30 September 2008, 中国中医药出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791131A (en) * | 2020-12-30 | 2021-05-14 | 茂名市人民医院 | Nasal cavity cold compress gel pastes |
| CN112791131B (en) * | 2020-12-30 | 2023-03-10 | 茂名市人民医院 | Nasal cavity cold compress gel pastes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689010B (en) | Medicine for hog house disinfection | |
| Dunglison | Medical Lexicon: A Dictionary of Medical Science... | |
| CN105251011B (en) | A kind of spray-filming agent and preparation method thereof for superficial burns | |
| Moghbel et al. | Wound healing and toxicity evaluation of Aloe vera cream on outpatients with second degree burns | |
| Dorland | Dorland's pocket medical dictionary | |
| CN105899221A (en) | Dermatological composition based on algae and olive leaf extracts | |
| CN109833431A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| CN107823337A (en) | A kind of allergic rhinitis oil formula and its preparation technology | |
| Blumgarten | Textbook of Materia Medica | |
| CN110269839A (en) | A kind of application of cannabidiol CBD and its nano-emulsion in nettle rash or/and preparation for treating rhinitis | |
| CN103721138B (en) | A kind of traditional Chinese medicine for external application and its preparation method treating rosacea | |
| CN110974861A (en) | Blumea balsamifera oil liposome | |
| CN107184815A (en) | It is a kind of to treat tuberculous ulcer, Chinese medicine composition of sinus and its preparation method and application | |
| CN102145072A (en) | Traditional Chinese medicine composition for treating infantile eczema and dermatitis skin diseases | |
| CN1306941C (en) | Skin perparation for external use containing purpuricenus temminckii frass as the active ingredient | |
| CN104083406A (en) | Compound disinfectant and preparation method thereof | |
| CN109091521A (en) | A kind of Chinese medicine decontamination preparation and preparation method thereof | |
| CN110051829A (en) | Application of the hay bacillus fibrinolysin in treatment rhinitis drug | |
| CN109939038A (en) | A kind of bath foam and preparation method thereof of natural bacteriostatic anti-inflammatory | |
| Lescher | Pathology for the physical therapist assistant | |
| Shreeve | Alternative Dictionary Of Symptoms And Cures: A Comprehensive Guide to Diseases and Their Orthodox and Alternative Remedies | |
| CN109939039A (en) | A kind of Traditional Chinese medicinal hand lotion of inhibiting bacteria and diminishing inflammation and preparation method thereof | |
| CN113509487A (en) | Preparation of skin allergy pruritus relieving liquid and preparation of wet tissue | |
| Schrader | Traditional cataract treatment and the healers perspective: dialogue with western science and technology in Nigeria, West Africa | |
| CN107912462A (en) | A kind of clinical laboratory's disinfection Chinese and western medicinal composition and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180323 |
|
| RJ01 | Rejection of invention patent application after publication |